
[Glu1]-Fibrinopeptide B
CAS No. 103213-49-6
[Glu1]-Fibrinopeptide B ( —— )
产品货号. M30562 CAS No. 103213-49-6
[Glu1]-Fibrinopeptide B is derived from fibrinopeptide B amino acid residues 1-14. Human fibrinopeptide B (hFpB), a thrombin-derived proteolytic cleavage product of the fibrinogen B beta-chain, to stimulate neutrophils (PMN), monocytes, and fibroblasts.
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥5119 | 有现货 |
![]() ![]() |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称[Glu1]-Fibrinopeptide B
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述[Glu1]-Fibrinopeptide B is derived from fibrinopeptide B amino acid residues 1-14. Human fibrinopeptide B (hFpB), a thrombin-derived proteolytic cleavage product of the fibrinogen B beta-chain, to stimulate neutrophils (PMN), monocytes, and fibroblasts.
-
产品描述[Glu1]-Fibrinopeptide B is derived from fibrinopeptide B amino acid residues 1-14. Human fibrinopeptide B (hFpB), a thrombin-derived proteolytic cleavage product of the fibrinogen B beta-chain, to stimulate neutrophils (PMN), monocytes, and fibroblasts. (In Vitro):hFpB causes directed cell migration of PMN and fibroblasts that is optimal at approximately 10 nM. hFpB causes a rapid, dose-dependent increase in PMN cytoskeletal associated actin, but unlike fMLP, hFpB does not cause PMN aggregation, release of lysosomal enzymes (lysozyme and beta-glucuronidase), or the production of superoxide anion. These results suggest that hFpB may have a role in recruiting PMN and fibroblasts at sites of fibrin deposition and turnover. The capacity of hFpB to cause PMN chemotaxis without causing concurrent release of lysosomal enzymes or the production of superoxide anion is further evidence for the complexity of PMN responses to chemotactic agents.
-
体外实验hFpB causes directed cell migration of PMN and fibroblasts that is optimal at approximately 10 nM. hFpB causes a rapid, dose-dependent increase in PMN cytoskeletal associated actin, but unlike fMLP, hFpB does not cause PMN aggregation, release of lysosomal enzymes (lysozyme and beta-glucuronidase), or the production of superoxide anion. These results suggest that hFpB may have a role in recruiting PMN and fibroblasts at sites of fibrin deposition and turnover. The capacity of hFpB to cause PMN chemotaxis without causing concurrent release of lysosomal enzymes or the production of superoxide anion is further evidence for the complexity of PMN responses to chemotactic agents.
-
体内实验——
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number103213-49-6
-
分子量1570.6
-
分子式C66H95N19O26
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称Sequence:Glu-Gly-Val-Asn-Asp-Asn-Glu-Glu-Gly-Phe-Phe-Ser-Ala-Arg
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
Senior RM, et al. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest. 1986 Mar;77(3):1014-9.
产品手册




关联产品
-
AEOL-10150 pentachlo...
AEOL-10150 五氯化物是一种金属卟啉催化抗氧化剂。 AEOL-10150 五氯化物也是一种超氧化物歧化酶模拟物。它可以保护肺部免受辐射引起的损伤。
-
Oxindole
羟吲哚是一种芳香族杂环结构单元。 2-二氢吲哚酮衍生物已成为激酶抑制剂研究中的先导化合物。 羟吲哚结构已用于受体酪氨酸激酶(RTK)抑制剂,如SU4984和intedanib,RTK家族代表了抗癌药物开发的重要治疗靶点。
-
Pirmenol
Pirmenol 是一种具有口服活性的抗心律失常剂。Pirmenol 通过阻断毒蕈碱性受体 (mAchR) 来抑制 IK.ACh (IC50: 0.1 μM)。可用于心血管疾病的研究,如心房颤动。Pirmenol 通过阻断毒蕈碱性受体 (mAchR) 来抑制 IK.ACh (IC50: 0.1 μM)。